Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $145,316.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $85.48, for a total transaction of $145,316.00. Following the sale, the executive vice president owned 98,185 shares of the company’s stock, valued at approximately $8,392,853.80. The trade was a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Jon Brown also recently made the following trade(s):

• On Tuesday, September 15th, Michael Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $84.04, for a total transaction of $142,868.00.

DexCom Trading Down 0.1%

NASDAQ:DXCM traded down $0.06 on Monday, hitting $85.98. The stock had a trading volume of 2,590,456 shares, compared to its average volume of 4,972,389. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The stock has a market cap of $32.45 billion, a price-to-earnings ratio of 33.98, a PEG ratio of 1.44 and a beta of 1.48. The company has a fifty day moving average price of $87.61 and a two-hundred day moving average price of $75.96. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.48 EPS. Equities research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DexCom

Large investors have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in DexCom in the 2nd quarter valued at approximately $173,237,000. Deutsche Bank AG acquired a new position in DexCom during the second quarter worth $164,035,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in DexCom by 15.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock worth $758,487,000 after purchasing an additional 1,515,702 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of DexCom by 271.4% during the first quarter. SG Americas Securities LLC now owns 2,065,277 shares of the medical device company’s stock worth $129,699,000 after buying an additional 1,509,219 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of DexCom during the second quarter worth $89,940,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DXCM. TD Cowen reiterated a “buy” rating and issued a $95.00 price objective on shares of DexCom in a research report on Friday, September 18th. Weiss Ratings upgraded DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, October 6th. BTIG Research upped their price target on DexCom from $90.00 to $96.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Royal Bank Of Canada reiterated an “outperform” rating and set a $105.00 price target (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, DexCom currently has a consensus rating of “Buy” and an average target price of $92.43.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.